Cargando…
Hodgkin's Lymphoma in Children and Adolescents: A Saint Petersburg Hodgkin's Lymphoma Group Study
Purpose. Prospective analysis of the efficacy of the original protocol SPbHL-05 was performed. Patients and Methods. Sixty patients with Hodgkin's lymphoma (HL) aged less than 18 years old were treated in accordance with SPbHL-05 from January 2000, to July 2009. In induction chemotherapy we use...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136222/ https://www.ncbi.nlm.nih.gov/pubmed/21772850 http://dx.doi.org/10.1155/2011/958435 |
_version_ | 1782208187096629248 |
---|---|
author | Kulyova, Svetlana A. Kolygin, Boris A. |
author_facet | Kulyova, Svetlana A. Kolygin, Boris A. |
author_sort | Kulyova, Svetlana A. |
collection | PubMed |
description | Purpose. Prospective analysis of the efficacy of the original protocol SPbHL-05 was performed. Patients and Methods. Sixty patients with Hodgkin's lymphoma (HL) aged less than 18 years old were treated in accordance with SPbHL-05 from January 2000, to July 2009. In induction chemotherapy we used VBVP and ABVD schedules followed by involved-field radiotherapy. Fourteen patients (23,3%) with 0–2 adverse factors (the favourable group) received two cycles of chemotherapy (VBVP), 25 children (41,7%) with 3-4 unfavorable signs (the intermediate group) received two cycles of VBVP alternating with two cycles of ABVD, 21 patient (35%) who had 5 or more adverse prognostic factors (the unfavourable group) received three cycles of VBVP alternating with three cycles of ABVD. Results. With a median follow-up of 68 months, overall survival (OS) at 5 years is 91.3%, event-free survival (EFS) is 82.8%. OS in the favourable and intermediate risk group were 100%, EFS were 92,9% and 90,7%, respectively, OS and EFS in unfavourable risk group—77,1% and 55,6%, respectively. Conclusion. The identification of prognostic risk factors and using medicines with less prominent side effects would be of major importance in the development of new strategies of treatment for childhood HL. |
format | Online Article Text |
id | pubmed-3136222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31362222011-07-19 Hodgkin's Lymphoma in Children and Adolescents: A Saint Petersburg Hodgkin's Lymphoma Group Study Kulyova, Svetlana A. Kolygin, Boris A. J Oncol Clinical Study Purpose. Prospective analysis of the efficacy of the original protocol SPbHL-05 was performed. Patients and Methods. Sixty patients with Hodgkin's lymphoma (HL) aged less than 18 years old were treated in accordance with SPbHL-05 from January 2000, to July 2009. In induction chemotherapy we used VBVP and ABVD schedules followed by involved-field radiotherapy. Fourteen patients (23,3%) with 0–2 adverse factors (the favourable group) received two cycles of chemotherapy (VBVP), 25 children (41,7%) with 3-4 unfavorable signs (the intermediate group) received two cycles of VBVP alternating with two cycles of ABVD, 21 patient (35%) who had 5 or more adverse prognostic factors (the unfavourable group) received three cycles of VBVP alternating with three cycles of ABVD. Results. With a median follow-up of 68 months, overall survival (OS) at 5 years is 91.3%, event-free survival (EFS) is 82.8%. OS in the favourable and intermediate risk group were 100%, EFS were 92,9% and 90,7%, respectively, OS and EFS in unfavourable risk group—77,1% and 55,6%, respectively. Conclusion. The identification of prognostic risk factors and using medicines with less prominent side effects would be of major importance in the development of new strategies of treatment for childhood HL. Hindawi Publishing Corporation 2011 2011-05-23 /pmc/articles/PMC3136222/ /pubmed/21772850 http://dx.doi.org/10.1155/2011/958435 Text en Copyright © 2011 S. A. Kulyova and B. A. Kolygin. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Kulyova, Svetlana A. Kolygin, Boris A. Hodgkin's Lymphoma in Children and Adolescents: A Saint Petersburg Hodgkin's Lymphoma Group Study |
title | Hodgkin's Lymphoma in Children and Adolescents: A Saint Petersburg Hodgkin's Lymphoma Group Study |
title_full | Hodgkin's Lymphoma in Children and Adolescents: A Saint Petersburg Hodgkin's Lymphoma Group Study |
title_fullStr | Hodgkin's Lymphoma in Children and Adolescents: A Saint Petersburg Hodgkin's Lymphoma Group Study |
title_full_unstemmed | Hodgkin's Lymphoma in Children and Adolescents: A Saint Petersburg Hodgkin's Lymphoma Group Study |
title_short | Hodgkin's Lymphoma in Children and Adolescents: A Saint Petersburg Hodgkin's Lymphoma Group Study |
title_sort | hodgkin's lymphoma in children and adolescents: a saint petersburg hodgkin's lymphoma group study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136222/ https://www.ncbi.nlm.nih.gov/pubmed/21772850 http://dx.doi.org/10.1155/2011/958435 |
work_keys_str_mv | AT kulyovasvetlanaa hodgkinslymphomainchildrenandadolescentsasaintpetersburghodgkinslymphomagroupstudy AT kolyginborisa hodgkinslymphomainchildrenandadolescentsasaintpetersburghodgkinslymphomagroupstudy |